Item 5.02 Departures of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers

This Current Report on Form 8-K/A of Lyell Immunopharma, Inc. (the "Company") amends the Company's Current Report on Form 8-K dated September 29, 2021 and filed with the Securities and Exchange Commission on September 30, 2021 (the "Original Filing") to correct a typo referring to the date on which Dr. Richard Klausner will no longer be an employee of the Company. On September 29, 2021, Dr. Klausner informed the Company that he will be resigning from his position as Executive Chairman of the Company and will no longer be an employee, effective October 1, 2021.

Except as described herein, no other changes have been made to the Original Filing.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses